Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey swift, this is dedicated to you. Thanks for not replying to any of my e-mails.
I know you read this board. So, this is for you.
I for one will not go away. I'm in this until the end. Good or bad, I'll be here.
Fox, do you believe they are undergoing phase 3 trials right now? Or is this just in reference to that 82 person trial that took place a while back? Thanks
In my opinion, it's nothing more than a smear campaign.
I believe the silence started when Pandey was still in control.
I came up with roughly 1.7 million U.S.
http://coinmill.com/NGN_calculator.html#NGN=200000000
previous link goes to page 2
This takes you to page 1.
http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=514791&pageID=1&sk=&date=
Article mentioning Xechem International and the drug treatment legion speaks of ad nauseam.
http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=514791&sk=&date=&pageID=2
Huh? Check out pg.242
http://www.nxtbook.com/nxtbooks/medimedia/pt_200804/index.php?startid=242
1st paragraph
Probably been brought on the board, but I hadn't seen it.
Thanks for the insight wearelesion. No need to reply. I know you only have one post remaining. Nice to see you used the 1st 2 so wisely, he he.
Somebody that frequents this board had a connection at one time. That connection is longer available, I guess. Whoever it was, also had to pay for the pics.
The most recent pictures are in the I box.
Ding! One post remaining for the day.
So glad you're amused by other peoples misfortunes.
Don't mean to be a wet blanket,but that was told to us by a poster on this board. Not saying that they're wrong, but it hasn't happened.
Posted by: LOCHUTE
In reply to: None Date:4/17/2008 10:38:41 AM
Post #of 178519
Since the market has been open now for an hour, and our traded volume is 0 for the day, It would be interesting to see how many people that frequent IHUB actually look at the XKEM board on a daily basis. This could be useful in determining how many are watching and waiting to buy in on news.
So if you are willing to post, post the next number after the last posted number.
I will start
Here you go Lochute.
IN THE HIGH COURT OF DELHI AT NEW DELHI
CS(OS) 2151/2007
XECHEM INTERNATIONAL, INC, and ANR ..... Plaintiff
Through Mr.Sindhu Sinha
versus
XECHEM(INDIA) PVT.LTD and ORS ..... Defendent
Through Mr.Rahul Sharma for D-1 to 4
CORAM:
HON'BLE MS. JUSTICE HIMA KOHLI
O R D E R
11.03.2008
At joint request of counsels for the parties, who state that negotiations
for settlement are going on between them, list on 24.4.2008, in the category of
`Directions?.
HIMA KOHLI,J
MARCH 11, 2008
`ns'
39
http://courtnic.nic.in/dhcorder/dhcqrydisp_O.asp?pn=48353&yr=2008
Mostly old info, but still interesting.
New to me, not sure if everyone has seen this.
MyDocHub Blog
Your Health|Post|Ask|Discover
Blog Archives Register
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
« ClubPenguin.com is Safe Haven for KidsNew Warning for Cancer Drug Rituxan »
--------------------------------------------------------------------------------
Photo Project Sheds Light on Sickle Cell Anemia
Published by Dafé March 16th, 2007 in Dafé’s Café - Daily Dose of Medical News and MyDocHub.
Doctor WatchDog Notification Service
Project gives them a voice to share with others:
Inheriting Sickle Cell Genes
Photovoice, a Seattle-area photo project that enables teenagers to share their life experiences with a debilitating disease such as sickle cell anemia, gives a visual description of kids living with the disease. Sickle cell anemia is a serious disease in which the body makes abnormally shaped red blood cells, causing pain, organ damage and a low blood count. Seema Mhatre, Photovoice’s coordinator, said: “Sometimes we give cameras to people who don’t feel like they have power and it helps them create change. When these kids have pain crises, they have to be admitted to the hospital many times and they sometimes don’t feel like they’re understood.”
SICKLE CELL ANEMIA
Sickle cell anemia is a serious disease in which the body makes abnormally shaped red blood cells, causing pain, organ damage and a low blood count.
It’s a genetic disorder affecting about 72,000 Americans. There is no cure. Pain medication and blood transfusions are common treatments. One in 600 African Americans and one in every 1,000-1,400 Hispanic Americans are born with the disease.
While the disease in the U.S. most commonly affects people of African descent, people with ancestors from South America, Cuba, Central America, Saudi Arabia, India and Mediterranean countries such as Turkey, Greece and Italy also can be affected.
Source: National Heart, Lung and Blood Institute.
Share This
Sphere It
5 Responses to “Photo Project Sheds Light on Sickle Cell Anemia”
Feed for this Entry Trackback Address
--------------------------------------------------------------------------------
1 Ron
Jan 17th, 2008 at 8:15 pm
A treatment made from natural plants is reported to greatly reduce the number and severity of SCD crises. It is Nicosan and is not available in the US at this time.
2 angel
Feb 28th, 2008 at 8:41 pm
So where can it be found?
3 Aslepius
Mar 6th, 2008 at 12:46 am
Here is the latest on Nicosan/Niprisan a treatment for sickle cell anemia that has orphan drug status with both the FDA and E.U. The only thing holding it back is the pending investigational drug applications. It has completed phase IIb clinical trials.
This drug could be obtained for use in the United States if a concerned group of patients would enlist the aid of a doctor to apply for the FDA’s expanded access program. It is a way for a non-toxic drug which is not approved to be made available for conditions where no approved drug is as safe. This drug shows a more than competitive success rate with none of the side effects of hydroxyurea.
United Nations Economic Commission For Africa
Book Of Abstracts
Science With Africa Conference
March 3-7, 2008
page 30
Evaluation of Niprisan (Herbal Medicine) for the Management of Sickle Cell
Anaemia
Charles Wambebe and Hadiza Khamofu, International Biomedical Research in Africa, Abuja,
Nigeria, wambebe@yahoo.com, Joseph Okogun, Nathan Nasipuri and Karynius Gamaniel,
National Institute for Pharmaceutical Research and Development, Abuja, Nigeria.
About 70% of all sickle cell anemia (SCA) subjects reside in Africa, estimated at over 12 million. The prevalence of SCA is estimated at over 2% while infant mortality is about 8% and survival rate of SCA babies in rural areas by five years of age is about 20%. These statistics indicate that SCA is probably the most neglected (and sometimes forgotten by health authorities) serious public health disorder with serious mortality and morbidity rates in Africa. The objective was to undertake pre-clinical and clinical assessments of a herbal extract vis-à-vis management of sickle cell anemia using Good Laboratory Practice and Good Clinical Practice principles respectively. In Africa, there is no standard treatment for sickle cell anemia, only palliative management is generally available. In view of this situation, most
SCA subjects use herbal medicines. NIPRISAN is a standardized extract from four medicinal/food plants: Piper guineenses seeds, Pterocarpus osun stem, Eugenia caryophyllum fruit and Sorghum bicolor leaves. Short term toxicity study indicated that NIPRISAN was safe in laboratory animals. Bio-activity guided fractionation show that vanillin and aromatic aldehydes may be the bioactive moieties. NIPRISAN reversed sickled red blood cells and
protected them from being sickled when exposed to low oxygen tension. NIPRISAN dose- dependently delayed polymer formation of haemoglobin S. NIPRISAN induced 85% increased solubility of deoxy haemoglobin S. The in vivo efficacy study was undertaken at Children Hospital of Philadelphia, USA. Histological examination of lungs of control Tg transgenic mice carrying human sickle haemoglobin showed entrapment of massive numbers
of sickled cells in alveolar capillaries. NIPRISAN significantly cleared the lungs of sickled cells. Furthermore, NIPRISAN induced profound effect on the survival time of Tg mice under hypoxic conditions (p
4 Aslepius
Mar 6th, 2008 at 12:50 am
NICOSAN for the Treatment of Sickle Cell Disease
Although this drug was developed in
Nigeria, the man behind it, Dr. Ramesh Pandey is a
distinguished biochemist who has worked for the
National Cancer Institute’s (NCI) Frederick Cancer
Research Center as a Senior Scientist, Head of the
Chemistry Section, Abbott Pharmaceuticals and
produced the first commercially viable generic version
of Vancomycin for Lyphomed Inc., a Visiting Professor
at the Waksman Institute of Microbiology at Rutgers,
the State University of New Jersey, holds patents for
biotechnology analysis and rare drug production
processes. He also holds several US and international
patents for paclitaxel and its new analogs. He is a
member of the Editorial Board of the International
Journal of Antibiotics and of several professional
societies. He has been awarded several grants from
NASA, NCI and NIH. The drug NICOSAN has been granted
Orphan Drug Status by both the FDA and E.U..
NIPRISAN / NICOSAN
It has been tested through phase IIb clinical trials and
found to be highly efficacious. Phase III trials have yet
to be completed however it was approved for sale in Nigeria
based on phase IIb trials and toxicity studies which showed
it to be safe and non-toxic.
Double-blind, placebo-controlled, randomised cross-over
clinical trial of NIPRISAN® in patients with Sickle Cell
Disorder
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B7GVW-4DS346T-1S&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=211981d545303693affebb8c012d2cac
Efficacy of Niprisan in the prophylactic management of
patients with sickle cell disease
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VS8-43DFJCH-G&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=10528ecbab3ec7e977301fb9f2688ef6
NIPRISAN — Nix-0699 Toxicity Studies
http://www.biospace.com/news_story.aspx?StoryID=15890720&full=1
Niprisan (Nix-0699) improves the survival rates of
transgenic sickle cell mice under acute severe hypoxic
conditions
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2141.2003.04536.x?journalCode=bjh
THE DEVELOPMENT OF NICOSANTM/HEMOXINTM
A DRUG FOR THE MANAGEMENT OF SICKLE CELL DISEASE.
HISTORICAL BACKGROUND
http://shestco.net/5_tech_park/nicosan.pdf
NIPRISAN Case, Nigeria
A Report for GenBenefit (2007)
http://www.theparliament.com/NR/rdonlyres/F46A1A12-0A1A-41DA-9F5D-A11486CA9BFA/0/Nigerian_Case.pdf
This drug is a major advancement in the treatment of sickle
cell disease unfortunately it is not available in the U.S..
Although the compound has been granted orphan drug status
by the FDA and the regulatory body of the European Union,
to date investigational drug applications for the approval
process have yet to be submitted. Getting a drug approved
in either area is extremely expensive. Until there is
funding available to proceed with the FDA and EU
applications it will be difficult for non-Nigerians to
obtain the drug.
I do say difficult but it is not impossible. If you have a
hematologist or hemoncologist who is willing to put fourth
the effort there are special dispensations available
through the FDA for the importation of unapproved drugs on
a compassionate use basis.
“Expanded access program (EAP). EAPs are typically designed
to provide widespread access to a drug that has proven
efficacy in clinical trials but is still awaiting FDA
approval. They’re similar to standard clinical trials with
a specific treatment plan and certain FDA requirements, but
they have looser patient eligibility criteria. More than
23,000 U.S. cancer patients enrolled in an EAP for Iressa
before it was FDA-approved, for example.”
“Single patient use. This program offers an experimental
drug to an individual patient, rather than a group. The FDA
approves these uses on a case-by-case basis. Decisions are
based on other treatments already available and information
about the drug’s efficacy and potential toxicities.”
http://www.curetoday.com/backissues/v3n3/departments/specialreport/index.html
To date I have no knowledge that anyone has sought any
single use or expanded access from the FDA for Nicosan.
Unfortunately regardless of the dissemination of this
information thus far no one has put forth the effort to
obtain the drug for use.
If just one person would start the ball rolling with a
caring and concerned medical practitioner it could open up
the drug for wide spread use by tens of thousands of
patients across the U.S. Unfortunately thus far the general
response I receive is that people don’t believe that their
physician would be interested in going to this sort of
effort nor do they themselves seem to be inclined to seek
the use of a treatment that could potentially end their
crises.
There has to be at least one physician out there who has
enough care and concern for his patients to be willing to
put forth the effort necessary to obtain this medication
legally. I urge anyone who is effected by sickle cell to
approach their physicians with this information and attempt
to obtain this treatment not only for themselves but for
all patients who could potentially benefit from it’s use.
We already know the benefits of the treatments available in
the U.S. and the E.U.. In many cases they are only
marginally effective or in the case of hydroxyurea cause
side effects so serious that many choose not to use it as
treatment. Here we have an opportunity to use a treatment
that has been shown to be highly effective, eradicating
crises in the majority of patients and reducing crises by
50% in the most refractory cases.
Although the clinical trial group was what the casual
reader might interpret as quite small it is common for
drugs which fall into the orphan drug category to use small
sample groups. Many orphan drugs have been approved based
on very small phase II and phase IIb clinical trials in the
U.S. In the case of FDA fast track status, a drug may be
approved during phase II trials if the drug shows
significant advantage over current approved therapies for
life threatening illness.
Fast Track Designation is a program that, if granted, is
designed to facilitate the development and expedite the
review of new drugs, thereby allowing the FDA to approve
drugs used to treat a serious condition or a
life-threatening disease with less safety data following
the conclusion of phase II studies, rather than phase III,
the normal practice.
The main criterion for a Fast Track Designated drug is the
potential to treat a life-threatening illness or fill a
major unmet medical need. Fast Track may be submitted with
the IND or at any time during the clinical development of
the drug. The Fast Track designation may allow a company’s
application to follow Priority Review, Standard Review, or
a Rolling Review of the application.
http://www.fda.gov/CbER/gdlns/fsttrk.pdf
Nicosan by Western standards is an extremely inexpensive
drug. It is available in Nigeria without prescription at
$23/month for adults and child doses at $18/month.
Here is a link to the company and product website.
http://xechemnigeria.com/products.htm
I sincerely hope that you find this information helpful. I
would encourage you to forward and post this information
to any person, blog or website where persons effected by
sickle cell anemia can have access to this information.
Feel free to write me with any questions you may have.
NicosanForSickleCell@yahoo.com
5 Aslepius
Mar 20th, 2008 at 4:33 pm
United Nations Economic Commission For Africa
Book Of Abstracts
Science With Africa Conference
March 3-7, 2008
page 30
Evaluation of Niprisan (Herbal Medicine) for the Management of Sickle Cell
Anaemia
Charles Wambebe and Hadiza Khamofu, International Biomedical Research in Africa, Abuja,
Nigeria, wambebe@yahoo.com, Joseph Okogun, Nathan Nasipuri and Karynius Gamaniel,
National Institute for Pharmaceutical Research and Development, Abuja, Nigeria.
About 70% of all sickle cell anemia (SCA) subjects reside in Africa, estimated at over 12 million. The prevalence of SCA is estimated at over 2% while infant mortality is about 8% and survival rate of SCA babies in rural areas by five years of age is about 20%. These statistics indicate that SCA is probably the most neglected (and sometimes forgotten by health authorities) serious public health disorder with serious mortality and morbidity rates in Africa. The objective was to undertake pre-clinical and clinical assessments of a herbal extract vis-à-vis management of sickle cell anemia using Good Laboratory Practice and Good Clinical Practice principles respectively. In Africa, there is no standard treatment for sickle cell anemia, only palliative management is generally available. In view of this situation, most
SCA subjects use herbal medicines. NIPRISAN is a standardized extract from four medicinal/food plants: Piper guineenses seeds, Pterocarpus osun stem, Eugenia caryophyllum fruit and Sorghum bicolor leaves. Short term toxicity study indicated that NIPRISAN was safe in laboratory animals. Bio-activity guided fractionation show that vanillin and aromatic aldehydes may be the bioactive moieties. NIPRISAN reversed sickled red blood cells and
protected them from being sickled when exposed to low oxygen tension. NIPRISAN dose- dependently delayed polymer formation of haemoglobin S. NIPRISAN induced 85% increased solubility of deoxy haemoglobin S. The in vivo efficacy study was undertaken at Children Hospital of Philadelphia, USA. Histological examination of lungs of control Tg transgenic mice carrying human sickle haemoglobin showed entrapment of massive numbers
of sickled cells in alveolar capillaries. NIPRISAN significantly cleared the lungs of sickled cells. Furthermore, NIPRISAN induced profound effect on the survival time of Tg mice under hypoxic conditions (p
http://mydochub.com/blog/index.php/2007/03/16/photo-project-sheds-light-on-sickle-cell-anemia/
That isn't new. It's said that for many months now.
Posted by: HSCOTTENGLISH
In reply to: None Date:5/18/2007 10:32:39 AM
Post #of 177148
Hi All,
My name is Scott English and I am the new Director of Investor Relations for Xechem. I am looking forward to helping Xechem reach its true potential and communicating openly and freely with all of our investors. Please feel free to call me at anytime to discuss as I look forward to answering any questions I can.
(732) 247-3300 ex37
Anybody see this?
New sickle cell treatment offers hope for sufferers
Updated: March 5, 2008 03:24 PM CST
By Lori Lyle
WAVE 3 Medical Reporter
LOUISVILLE (WAVE) -- Sickle cell disease affects million of people. Researchers know what causes it and how it affects the body, but there's no cure. Medical reporter Lori Lyle has more on what could be the next best thing.
Researcher Donald Abraham is excited about a potential new treatment for sickle cell disease.
"It's the best thing I have seen in my what, 37 years in this field. It's by far the best. It has the best chance," says Dr. Abraham, a medicinal chemist.
"It" is a treatment that could change sickle shaped blood cells back to normal.
"Anti sickling will move it back to the donut shape, going from this to the donut shape," Dr. Abraham said.
Healthy red blood cells are round and flexible and easily squeezed through blood vessels. In sickle cell disease, the cells are stiff and crescent shaped. They get stuck and block the flow of oxygen-rich blood to the limbs and organs.
"Your joints ache, your stomach aches, your back aches, you can ache all over with it," says Lucy Brown, a a 48 year old sickle cell patient.
She was born with sickle cell disease. She takes medication to control painful episodes.
"If there was something that could stop them completely, that would be a blessing. Yes, it would," she says.
Dr. Abraham's anti-sickling molecule may be the answer to her prayers.
"This molecule, 5-HMF, really is a breakdown product in many foods and in plants. So, it's really common in nature," says Dr. Abraham.
Researchers at Virginia Commonwealth University say 5-HMF works by attaching itself to red blood cells, increasing their supply of oxygen.
"What you want to do to treat sickle cell is you want to oxygenate this because when it's in oxygenated red form, it won't sickle," Dr. Abraham says.
A drug containing the molecule is in the works. Until then, Lucy remains on pins and needles coping with the pain.
The National Heart, Lung and Blood Institute is funding studies on 5-HMF. It may take years before it's available to patients. Xechem International has already signed on to market the drug.
Online Reporter: Lori Lyle
Online Producer: Charles Gazaway
http://www.wave3.com/Global/story.asp?S=7433822&nav=menu3
Is anybody around on this board?
List of drugs with orphan drug status. Haven't seen this report before. Hemoxin mentioned.
http://www.phrma.org/files/Orphan%202007.pdf
Nothing important, but an interesting list of companies, possibly dealing with the same issues. Probably been posted here, but I hadn't seen it.
Sorry, my misktake. I forgot it was in India. I checked the time in Nigeria.
It's 5:30 pm over there right now. My guess is court is now over for the day.
Fiat, did you recieve confirmation from your source on the daliy production amount?
Good luck getting a reply from Swift. I've e-mailed him several times, and never gotten a response. I guess it doesn't hurt to try, though.
Thanks Fiat. Even if it's closer to the reported 50K, that would still be great news. You're info has given me hope.
Only one reason in my mind for them to be stockpiling. IF, that's in fact, what they're doing.
Fiat, are you saying they are actually producing 400,000 pills/day? Or, are you saying they are now capable of producing this amount? Thanks
中, 𰵀 𘚠, ✐
Just found Swift's e-mail. Any e-mail of Pandey's ever given on this board, were e-mails he had while with the company. Doubt he uses them any longer.
I know a few on this board had Pandey's phone #. For obvious reasons, they probably aren't willing to give that out.
Does anybody have Swift and Basu's e-mails addresses? Drifter, I believe you have posted them before. Please post so I can send something off to them. Thanks
Did anybody hear anything about the peer review that tool place this past Thurs? Haven't seen any posts about it.
Thanks Fox. Your info. is greatly appreciated.
GM Fox. I believe it was you that posted the dates for the upcoming peer review. I believe it is slotted for the 27th of Feb.
So, just a quick question for you. What happens post review, for the company? Probably a stupid question, but I'm not really familiar with the process.
It was removed from the board. GO XKEM